Druck Icon

Eckert & Ziegler Annual Financial Statements Show Record Results

(Ad hoc press release)

Berlin, 29 March 2000. Eckert & Ziegler Strahlen- und Medizintechnik AG, a leading manufacturer of low-level radioactive sources of radiation for medical and industrial applications, has grown well above average during the 1999 fiscal year in comparison to the prior year. As the company reported at ist balance sheet press conference, revenues reached EUR 9.9 million (EUR 1.7 million, +482%). The results for its ordinary operations rose to EUR 1.2 million (EUR 0.04 million, +3061%). The DVFA/SG results after taxes increased to EUR 0.3 million (EUR -0.01 million). The DVFA/SG earnings per share amounted to EUR 0.11 (EUR -0.005). At the same time, the cash flow improved to eUR 2.5 million (EUR 1.6 million, +60%).

The reason for this exceptional development is the continued strong demand for low-level radioactive components for therapeutic purposes, above all for the treatment of coronary disorders and prostate cancer. "Among other factors, this demand stems from demographic developments and an improved level of early diagnosis", explains CEO Dr. Andreas Eckert. Eckert & Ziegler AG will be announcing all its figures during today's balance sheet press conference.

The Board of Directors